Compare SERV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERV | CDNA |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.2M | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | SERV | CDNA |
|---|---|---|
| Price | $9.20 | $17.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $18.80 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 3.1M | 539.5K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $872.80 | $15.37 |
| Revenue Next Year | $199.55 | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $4.66 | $10.96 |
| 52 Week High | $18.64 | $21.49 |
| Indicator | SERV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 37.34 |
| Support Level | $8.02 | $16.74 |
| Resistance Level | $11.00 | $17.09 |
| Average True Range (ATR) | 0.67 | 0.83 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 6.96 | 23.77 |
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.